B-cell lymphoma treatment responsiveness prediction using gene expression profiling

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need to identify predictive markers for the responsiveness of B-cell lymphoma patients to anti-CD40 antibody therapy, as not all B lymphoma cells are sensitive to this treatment.

Innovation Solution

Measuring the expression levels of specific marker genes such as IFITM1, CD40, RGS13, VNN2, LMO2, CD79B, CD22, BTG2, IGF1R, CD44, CTSC, EPDR1, UAP1, and PUS7 in B-cell lymphoma samples to predict responsiveness to anti-CD40 antibody treatment, using methods like qRT-PCR and immunohistochemistry, and calculating a sensitivity index to determine the likelihood of treatment response.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If anti-CD40 antibody therapy is administered to B-cell lymphoma patients, then anti-tumor activity is achieved in some patients, but not all B lymphoma cells are sensitive to the treatment

Engineering Contradiction:

Improvetreatment responsivenessVSAvoidtreatment applicability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent performs gene expression profiling and sensitivity index calculation before administering anti-CD40 antibody therapy to predict which patients will respond to treatment. This preliminary assessment allows clinicians to identify suitable candidates in advance, avoiding ineffective treatments and enabling personalized medicine approaches for B-cell lymphoma patients.

Inventive Principle:

Principle #10Preliminary action

2Measurement precision

If gene expression levels of multiple marker genes are measured to predict treatment responsiveness, then prediction accuracy is improved, but measurement complexity and cost increase

Engineering Contradiction:

Improveresponsiveness prediction accuracyVSAvoidmeasurement system complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent measures the expression levels of a specific panel of marker genes (including IFITM1, CD40, RGS13, VNN2, LMO2, CD79B, CD22, BTG2, IGF1R, CD44, CTSC, EPDR1, UAP1, and PUS7) to calculate a sensitivity index. This partial measurement approach focuses on the most predictive markers rather than analyzing the entire transcriptome, achieving sufficient prediction accuracy while reducing measurement complexity and cost compared to comprehensive genomic analysis.

Inventive Principle:

Principle #16Partial or excessive action

Data Source

PatentUS9068230B2Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies

Publication Date: 2015.06.30 GENENTECH INC

AI summary

The invention provides methods and kits useful for predicting or assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies.